4.8 Article

CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment

期刊

CELL
卷 184, 期 17, 页码 4512-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2021.07.015

关键词

-

资金

  1. Harvard Medical School Foundry award
  2. National Institutes of Health (NIH) [P01-CA240239, R01 AI084880, R01 CA218579, R01 AI123349, R01 CA206890, R01 CA204028, R01 AI134713, R21AI142667]
  3. BMBF project Oncoattract
  4. MSC network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union [955575]
  5. Bavarian Ministry for Economic Affairs (CARMOUFLAGE)
  6. ERC grant [756017]
  7. i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
  8. Melanoma Research Alliance Established Investigator Award [827872]
  9. Melanoma Research Foundation
  10. ISREC Foundation
  11. EMBO fellowship [ALTF534-2015]
  12. Marie Curie Global Fellowship [750973]
  13. DFG [PR 1652/1-1, PR 1652/2-1]
  14. German Academic Scholarship Foundation
  15. LMU Prosa Scholarship
  16. Swiss National Science Foundation Early Postdoctoral Mobility Award [P3BEP3_165406]
  17. American Association for Cancer Research Basic Science Fellowship Program [18-4001-OZGA]
  18. Bloomberg Philanthropies
  19. Marie Curie Actions (MSCA) [955575, 750973] Funding Source: Marie Curie Actions (MSCA)

向作者/读者索取更多资源

The conversion of stem-like CTLs into effector-like CTLs involves chemotactic reprogramming with upregulation of chemokine receptor CXCR6. CXCR6 expression and IL-15 trans-presentation are crucial for the survival and local expansion of effector-like CTLs in the tumor microenvironment.
Cytotoxic T lymphocyte (CTL) responses against tumors are maintained by stem-like memory cells that selfrenew but also give rise to effector-like cells. The latter gradually lose their anti-tumor activity and acquire an epigenetically fixed, hypofunctional state, leading to tumor tolerance. Here, we show that the conversion of stem-like into effector-like CTLs involves a major chemotactic reprogramming that includes the upregulation of chemokine receptor CXCR6. This receptor positions effector-like CTLs in a discrete perivascular niche of the tumor stroma that is densely occupied by CCR7(+) dendritic cells (DCs) expressing the CXCR6 ligand CXCL16. CCR7(+) DCs also express and trans-present the survival cytokine interleukin-15 (IL-15). CXCR6 expression and IL-15 trans-presentation are critical for the survival and local expansion of effector-like CTLs in the tumor microenvironment to maximize their anti-tumor activity before progressing to irreversible dysfunction. These observations reveal a cellular and molecular checkpoint that determines the magnitude and outcome of anti-tumor immune responses.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

Zsofia D. Drobni, Olivier Michielin, Thiago Quinaglia, Daniel A. Zlotoff, Leyre Zubiri, Hannah K. Gilman, Sama Supraja, Bela Merkely, Veronika Muller, Ryan J. Sullivan, Kerry L. Reynolds, Michael J. Pittet, Rakesh K. Jain, Tomas G. Neilan

Summary: This retrospective study investigated the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and outcomes in patients treated with immune checkpoint inhibitors (ICIs). The results showed that hypertension patients who concomitantly took a RAAS inhibitor during ICI therapy had better overall survival. This benefit was particularly significant among patients with gastrointestinal and genitourinary cancers.

EUROPEAN JOURNAL OF CANCER (2022)

Review Immunology

Neutrophil phenotypes and functions in cancer: A consensus statement

Daniela F. Quail, Borko Amulic, Monowar Aziz, Betsy J. Barnes, Evgeniy Eruslanov, Zvi G. Fridlender, Helen S. Goodridge, Zvi Granot, Andres Hidalgo, Anna Huttenlocher, Mariana J. Kaplan, Ilaria Malanchi, Taha Merghoub, Etienne Meylan, Vivek Mittal, Mikael J. Pittet, Andrea Rubio-Ponce, Irina A. Udalova, Timo K. van den Berg, Denisa D. Wagner, Ping Wang, Arturo Zychlinsky, Karin E. de Visser, Mikala Egeblad, Paul Kubes

Summary: This article discusses the functional states and heterogeneity of neutrophils in cancer and provides a consensus statement on the controversies and solutions in neutrophil research. Further research is needed to understand the role of neutrophils in cancer and explore potential novel opportunities for cancer treatment.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Article Biotechnology & Applied Microbiology

Spatiotemporal multiplexed immunofluorescence imaging of living cells and tissues with bioorthogonal cycling of fluorescent probes

Jina Ko, Martin Wilkovitsch, Juhyun Oh, Rainer H. Kohler, Evangelia Bolli, Mikael J. Pittet, Claudio Vinegoni, David B. Sykes, Hannes Mikula, Ralph Weissleder, Jonathan C. T. Carlson

Summary: SAFE is a method for comprehensive longitudinal imaging of living cells using immunofluorescence, allowing multiparameter temporal and spatial imaging. It is non-toxic and functional in various living samples.

NATURE BIOTECHNOLOGY (2022)

Correction Oncology

Clinical relevance of tumour-associated macrophages (vol 27, pg 4205, 2021)

Mikael J. Pittet, Olivier Michielin, Denis Migliorini

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Review Oncology

Clinical relevance of tumour-associated macrophages

Mikael J. Pittet, Olivier Michielin, Denis Migliorini

Summary: The interaction of tumour-associated macrophages (TAMs) with cancer and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. The authors of this Review examine the diversity of TAMs in various cancer indications, which is being revisited with the advent of single-cell technologies, and discuss the functional roles of different TAM states, the prognostic and predictive value of TAM-related signatures as well as approaches involving TAMs that are currently being or will soon be tested in clinical trials.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

A neutrophil response linked to tumor control in immunotherapy

Jeremy Gungabeesoon, Nicolas A. Gort-Freitas, Mate Kiss, Evangelia Bolli, Marius Messemaker, Marie Siwicki, Mehdi Hicham, Ruben Bill, Peter Koch, Chiara Cianciaruso, Florent Duval, Christina Pfirschke, Michael Mazzola, Solange Peters, Krisztian Homicsko, Christopher Garris, Ralph Weissleder, Allon M. Klein, Mikael J. Pittet

Summary: Neutrophils accumulate in solid tumors and their abundance is associated with poor prognosis. In this study, the role of neutrophils in immunotherapy and tumor control was investigated. The results demonstrate that successful therapies can expand tumor neutrophil numbers and thereby contribute to antitumor effects.
Article Oncology

Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+Cancer Cells in Locally Advanced Pancreatic Cancer

Yves Boucher, Jessica M. Posada, Sonu Subudhi, Ashwin S. Kumar, Spencer R. Rosario, Liqun Gu, Heena Kumra, Mari Mino-Kenudson, Nilesh P. Talele, Dan G. Duda, Dai Fukumura, Jennifer Y. Wo, Jeffrey W. Clark, David P. Ryan, Carlos Fernandez-Del Castillo, Theodore S. Hong, Mikael J. Pittet, Rakesh K. Jain

Summary: In this study, we found that adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC) resulted in a 61% R0 surgical resection rate. By evaluating the effects of neoadjuvant LOS on the tumor microenvironment, we identified potential mechanisms of benefit. The results showed that LOS+FFX+CRT reduced the expression of immunosuppression and pro-invasion genes and was associated with improved overall survival (OS).

CLINICAL CANCER RESEARCH (2023)

Correction Immunology

The Spleen in Local and Systemic Regulation of Immunity (vol 39, pg 806, 2013)

Vincenzo Bronte, Mikael J. Pittet

IMMUNITY (2023)

Article Oncology

Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics

Lou Romanens, Prasad Chaskar, Rachel Marcone, Stephan Ryser, Jean-Christophe Tille, Raphael Genolet, Ketty Heimgartner-Hu, Killian Heimgartner, Jonathan S. Moore, Nicolas Liaudet, Guerkan Kaya, Mikael J. Pittet, Pierre-Yves Dietrich, Mauro Delorenzi, Daniel E. Speiser, Alexandre Harari, Petros Tsantoulis, Sana Intidhar Labidi-Galy

Summary: The spatial distribution of tumor-infiltrating lymphocytes (TIL) can predict breast cancer outcome and response to treatment. A new method called ST-FFPE has been developed to analyze formalin-fixed paraffin-embedded samples, allowing for the study of archival tissue. By examining different tumor compartments, this method can characterize the cellular composition of the tumor microenvironment.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P. Trefny, Richard Klar, Nicole Kirchhammer, Melanie Buchi, Julia Festag, Sven Michel, Rainer H. Kohler, Elham Jones, Andre Maaske, Abhishek S. Kashyap, Frank Jaschinski, Karen O. Dixon, Mikael J. Pittet, Alfred Zippelius

Summary: In this study, a high-affinity immunomodulatory IM-T9P1-ASO was developed to target both TLR9 and PD-L1, enhancing the therapeutic efficacy of immune checkpoint inhibitors. The results showed that IM-T9P1-ASO can effectively inhibit tumor growth and promote anti-tumor responses, suggesting its potential importance for cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Review Oncology

Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

David Andreu-Sanz, Sebastian Kobold

Summary: While CD8(+) T cells have been the focus of most cancer immunotherapy approaches, increasing evidence indicates that CD4(+) T cells also play a crucial role in tumor elimination. These T cells can differentiate into different subsets, which have diverse effects on tumor progression depending on the cytokine milieu. This review provides an overview of the role of T helper subsets in the immune system, their implications in cancer immunology, and their applications in adoptive T-cell therapy.

CANCERS (2023)

Article Oncology

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy

Theo Lorenzini, Bruno L. Cadilha, Hannah Obeck, Mohamed-Reda Benmebarek, Florian Maerkl, Stefanos Michaelides, Thaddaeus Strzalkowski, Daria Briukhovetska, Philipp Jie Mueller, Sayantan Nandi, Pia Winter, Lina Majed, Ruth Gruenmeier, Matthias Seifert, Svenja Rausch, Tobias Feuchtinger, Stefan Endres, Sebastian Kobold

Summary: This study investigates the design choices of immunostimulatory fusion protein (IFP) constructs for enhancing the therapeutic efficacy of CAR T cells. It finds that IFP variants with similar extracellular lengths to PD-1 show improved CAR T cell function and proliferation, leading to prolonged survival in a leukemia mouse model. These findings highlight the importance of mimicking the physiological interaction of PD-1 with PD-L1 in IFP design.

BRITISH JOURNAL OF CANCER (2023)

Article Multidisciplinary Sciences

CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers

Ruben Bill, Pratyaksha Wirapati, Marius Messemaker, Whijae Roh, Beatrice Zitti, Florent Duval, Mate Kiss, Jong Chul Park, Talia M. Saal, Jan Hoelzl, David Tarussio, Fabrizio Benedetti, Stephanie Tissot, Lana Kandalaft, Marco Varrone, Giovanni Ciriello, Thomas A. McKee, Yan Monnier, Maxime Mermod, Emily M. Blaum, Irena Gushterova, Anna L. K. Gonye, Nir Hacohen, Gad Getz, Thorsten R. Mempel, Allon M. Klein, Ralph Weissleder, William C. Faquin, Peter M. Sadow, Derrick Lin, Sara I. Pai, Moshe Sade-Feldman, Mikael J. Pittet

Summary: Tumor microenvironments (TMEs) have an impact on cancer progression and vary between patients. By studying tumor-to-tumor variation, researchers found that macrophage polarity defined by CXCL9 and SPP1 expression had a strong prognostic association. This study suggests that TMEs coordinate coherent responses that control human cancers, with macrophage polarity being a relevant and simple variable.

SCIENCE (2023)

Article Dermatology

Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance

Stefan Tukaj, Katja Bieber, Wiebke Pruessmann, Jasper N. Pruessmann, Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, Michael Kasperkiewicz

Summary: Healthy individuals with BP autoantibody reactivity have abnormal vitamin D levels and a specific cytokine profile.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

暂无数据